Compare
Dogwood Therapeutics, Inc. vs Shattuck Labs, Inc. vs Pyxis Oncology, Inc. vs Eton Pharmaceuticals, Inc.
| Latest fiscal year | Dogwood Therapeutics, Inc. DWTX | Shattuck Labs, Inc. STTK | Pyxis Oncology, Inc. PYXS | Eton Pharmaceuticals, Inc. ETON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.00M | $13.86M | $79.95M |
| Revenue growth (YoY) | n/a | -82.5% | -14.2% | +104.9% |
| Gross margin | n/a | n/a | 82.8% (computed) | 53.5% |
| Operating margin | n/a | n/m | -609.2% | -1.1% |
| Net margin | n/a | n/m | -574.5% | -5.8% |
| Net income | -$34.26M | -$48.81M | -$79.62M | -$4.60M |
| EPS (Diluted) | -$7.13 | -$0.70 | -$1.28 | n/a |
| Operating cash flow | -$15.62M | -$39.88M | -$63.50M | $10.52M |
| Free cash flow | n/a | -$39.95M | -$63.51M | $10.19M |
| Cash & equivalents | $6.52M | $54.19M | $15.42M | $25.94M |
| Total assets | $90.17M | $91.03M | $91.52M | $92.11M |
| Total liabilities | $15.27M | $8.64M | $38.11M | $65.96M |
| Shareholders' equity | $74.90M | $82.39M | $53.41M | $26.15M |
| Return on year-end equity | -45.7% | -59.2% | -149.1% | -17.6% |
| Shares outstanding | 29.74M | 63.28M | 62.69M | 27.05M |
Revenue, most recent five fiscal years
| Fiscal year | Dogwood Therapeutics, Inc. | Shattuck Labs, Inc. | Pyxis Oncology, Inc. | Eton Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.00M Ended 2025-12-31 | $13.86M Ended 2025-12-31 | $79.95M Ended 2025-12-31 |
| 1 year earlier | n/a | $5.72M Ended 2024-12-31 | $16.15M Ended 2024-12-31 | $39.01M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.66M Ended 2023-12-31 | n/a | $31.64M Ended 2023-12-31 |
| 3 years earlier | n/a | $652.0K Ended 2022-12-31 | n/a | $21.25M Ended 2022-12-31 |
| 4 years earlier | n/a | $30.02M Ended 2021-12-31 | n/a | $21.83M Ended 2021-12-31 |